Artisan Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Artisan Partners’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,837,924	Closed	-$23.7M	–	308
2023 Q1	$23.7M	Sell	2,837,924 -40,503	-1%	-$390K	0.04%	250
2022 Q4	$33M	Buy	2,878,427 +228,811	+9%	+$2.85M	0.06%	236
2022 Q3	$33.4M	Sell	2,649,616 -267,593	-9%	-$3.44M	0.06%	234
2022 Q2	$30.9M	Buy	2,917,209 +75,804	+3%	+$782K	0.05%	237
2022 Q1	$46.2M	Buy	2,841,405 +175	+0%	+$2.81K	0.06%	238
2021 Q4	$39.4M	Sell	2,841,230 -10,154	-0.4%	-$134K	0.05%	268
2021 Q3	$41M	Sell	2,851,384 -292,101	-9%	-$4.61M	0.05%	256
2021 Q2	$49.7M	Buy	3,143,485 +117,879	+4%	+$1.6M	0.06%	240
2021 Q1	$30.8M	Buy	+3,025,606	New	+$31.2M	0.04%	292

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Artisan Partners's BCRX Position: Q2 2023 in Review

Artisan Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2023, closing a stake of 2,837,924 shares — an estimated $23.7M sold.

Artisan Partners first reported a position in BCRX in Q1 2021 and held it in 9 quarters. The position peaked at $49.7M in Q2 2021. 235 funds tracked by Wall St. Rank hold BCRX as of Q2 2023.

Artisan Partners reported no remaining BioCryst Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Artisan Partners sold 2,837,924 BioCryst Pharmaceuticals shares in Q2 2023, an estimated $23.7M.
Artisan Partners first reported a position in BioCryst Pharmaceuticals in Q1 2021 and held it in 9 quarters.
Artisan Partners's BioCryst Pharmaceuticals position peaked at $49.7M in Q2 2021.
235 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2023.

Based on Artisan Partners's 13F filing for Q2 2023, filed 10 Aug 2023.